BIOLASE Reports 46% Revenue Growth In 2021 Third Quarter; Demand For Dental Lasers From New Customers Remains High And Continues To Fuel Growth
BIOLASE, Inc. (NASDAQ: BIOL) reported a 46% increase in net revenue for Q3 2021, totaling $9.5 million. A strong trend continued with 78% of U.S. laser sales from new customers. Laser system sales rose 64%, while consumables revenue grew 21%. Gross margin improved significantly to 51%, up 1,600 basis points. International revenue surged 101%. The company maintains a solid balance sheet with $33.4 million in cash. BIOLASE forecasts Q4 revenue to exceed pre-pandemic figures from 2019.
- Net revenue increased 46% to $9.5 million.
- 78% of U.S. laser sales from new customers.
- Laser system sales rose 64%.
- Gross margin improved to 51%, up 1,600 basis points.
- International revenue grew 101%.
- Net loss of $3.3 million, or $0.02 per share.
- Operating loss of $2.7 million, although improved from previous year.
FOOTHILL RANCH, Calif., Nov. 10, 2021 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for its third quarter ended September 30, 2021 and provided fourth quarter 2021 revenue guidance.
2021 Third Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise):
- Net revenue grew
46% to$9.5 million : 78% of U.S. laser sales came from new customers, continuing a positive trend- Approximately
35% of U.S. Waterlase sales came from dental specialists - Net revenue was
10% higher than third quarter of 2019, which was the last pre-pandemic comparable period - Laser system sales increased
64% - Consumables and other revenue increased
21% - U.S. and international revenue increased
25% and101% , respectively, as more dental practices were operating during the 2021 third quarter compared to the year-ago third quarter due to the COVID-19 pandemic - Gross margin was
51% , up 1,600 basis points, due to the higher year-over-year revenue, favorable revenue mix and higher average selling prices for products sold during the quarter - Maintained strong balance sheet, as cash and cash equivalents totaled
$33.4 million at quarter end
"Our strong third quarter performance continues to reflect the rising demand for our industry-leading dental lasers," commented John Beaver, President and Chief Executive Officer. "Our efforts to both educate and train dental specialists is leading to increased adoption across these large and largely untapped markets. In today's environment, the fact that BIOLASE lasers provide increased safety to dentists and their patients is generating a high level of acceptance by dental practitioners - and we expect this to be a driving force for the foreseeable future. Our industry-leading dental lasers aim to provide a better standard of care for dental procedures and seek to ensure a safer experience while reducing the risk of future procedure and business disruptions by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. Looking ahead, we expect significant year-over-year improvement across our key performance metrics, including revenue and gross margin in the fourth quarter as we continue to gain momentum with new customers and dental specialists."
2021 Third Quarter Financial Results
Net revenue for the third quarter of 2021 was
Gross margin for the third quarter of 2021 was
Adjusted EBITDA loss for the third quarter of 2021 was
Cash and cash equivalents totaled
2021 Fourth Quarter Revenue Guidance
The Company continues to experience high demand for its dental lasers and is currently forecasting revenue for the fourth quarter ending December 31, 2021 to be above the pre-pandemic revenue in the fourth quarter of 2019 of
Conference Call Information
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter ended September 30, 2021, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is (800) 367-2403. For international participants outside the U.S./Canada, the dial-in number is (334) 777-6978. For all callers, refer to the Conference ID 3599686. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".
An audio archive of the webcast will be available on the Investor Relations section of the BIOLASE website.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding BIOLASE's expected future revenue, gross margin and other key metrics; anticipated demand for BIOLASE's products and anticipated driving forces such as demand; and anticipated cash needs. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "forecast," "guidance," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the pandemic and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K and BIOLASE's quarterly report for the second quarter of 2021 filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Tables to Follow
BIOLASE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited, in thousands, except per share data)
| ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Net revenue | $ | 9,531 | $ | 6,539 | $ | 26,780 | $ | 14,260 | ||||||||
Cost of revenue | 4,689 | 4,265 | 15,157 | 9,692 | ||||||||||||
Gross profit | 4,842 | 2,274 | 11,623 | 4,568 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 3,451 | 2,678 | 10,315 | 7,475 | ||||||||||||
General and administrative | 2,479 | 2,300 | 8,613 | 7,446 | ||||||||||||
Engineering and development | 1,540 | 963 | 4,506 | 2,644 | ||||||||||||
Loss on patent litigation settlement | 29 | — | 190 | — | ||||||||||||
Total operating expenses | 7,499 | 5,941 | 23,624 | 17,565 | ||||||||||||
Loss from operations | (2,657) | (3,667) | (12,001) | (12,997) | ||||||||||||
Gain (Loss) on foreign currency transactions | (36) | 53 | (172) | (68) | ||||||||||||
Interest expense, net | (569) | (568) | (1,727) | (1,782) | ||||||||||||
Gain on debt forgiveness | — | — | 3,014 | — | ||||||||||||
Other income, net | — | 4,209 | — | 4,209 | ||||||||||||
Non-operating gain (loss), net | (605) | 3,694 | 1,115 | 2,359 | ||||||||||||
Loss before income tax (provision) benefit | (3,262) | 27 | (10,886) | (10,638) | ||||||||||||
Income tax (provision) benefit | (14) | (15) | 7 | (49) | ||||||||||||
Net income (loss) | (3,276) | 12 | (10,879) | (10,687) | ||||||||||||
Other comprehensive loss items: | ||||||||||||||||
Foreign currency translation adjustments | (90) | 111 | (173) | 167 | ||||||||||||
Comprehensive income (loss) | $ | (3,366) | $ | 123 | $ | (11,052) | $ | (10,520) | ||||||||
Net income (loss) | $ | (3,276) | $ | 12 | $ | (10,879) | $ | (10,687) | ||||||||
Deemed dividend on convertible preferred stock | (9) | (17,378) | (546) | (17,378) | ||||||||||||
Net loss attributable to common stockholders | $ | (3,285) | $ | (17,366) | $ | (11,425) | $ | (28,065) | ||||||||
Net loss per share attributable to common stockholders: | ||||||||||||||||
Basic | $ | (0.02) | $ | (0.21) | $ | (0.08) | $ | (0.56) | ||||||||
Diluted | $ | (0.02) | $ | (0.21) | $ | (0.08) | $ | (0.56) | ||||||||
Shares used in the calculation of net loss per share: | ||||||||||||||||
Basic | 151,941 | 81,341 | 145,809 | 50,366 | ||||||||||||
Diluted | 151,941 | 81,341 | 145,809 | 50,366 | ||||||||||||
BIOLASE, INC. CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands, except per share data)
| ||||||||
September 30, | December 31, | |||||||
2021 | 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 33,385 | $ | 17,564 | ||||
Restricted cash | 204 | 312 | ||||||
Accounts receivable, less allowance of | 3,637 | 3,059 | ||||||
Inventory | 14,062 | 11,157 | ||||||
Prepaid expenses and other current assets | 1,366 | 3,018 | ||||||
Total current assets | 52,654 | 35,110 | ||||||
Property, plant, and equipment, net | 889 | 782 | ||||||
Goodwill | 2,926 | 2,926 | ||||||
Right of use asset | 1,823 | 1,976 | ||||||
Other assets | 222 | 231 | ||||||
Total assets | $ | 58,514 | $ | 41,025 | ||||
LIABILITIES, REDEEMABLE PREFERRED STOCK AND | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,597 | $ | 2,651 | ||||
Accrued liabilities | 6,182 | 6,667 | ||||||
Deferred revenue, current portion | 2,278 | 1,905 | ||||||
Term loan, net of discount | 1,400 | — | ||||||
Total current liabilities | 13,457 | 11,223 | ||||||
Deferred revenue | 294 | 374 | ||||||
Warranty accrual | 472 | 384 | ||||||
Non current term loans, net of discount | 12,114 | 16,186 | ||||||
Non current operating lease liability | 1,557 | 1,774 | ||||||
Other liabilities | 298 | 1,056 | ||||||
Total liabilities | 28,192 | 30,997 | ||||||
Stockholders' equity: | ||||||||
Series F Preferred stock, par value | 34 | 118 | ||||||
Common stock, par value | 153 | 98 | ||||||
Additional paid-in capital | 292,948 | 261,573 | ||||||
Accumulated other comprehensive loss | (558) | (385) | ||||||
Accumulated deficit | (262,255) | (251,376) | ||||||
Total stockholders' equity | 30,322 | 10,028 | ||||||
Total liabilities, redeemable preferred stock and stockholders' equity | $ | 58,514 | $ | 41,025 | ||||
BIOLASE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands)
| ||||||||
Nine Months Ended | ||||||||
September 30, | ||||||||
2021 | 2020 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net loss | $ | (10,879) | $ | (10,687) | ||||
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
Depreciation and amortization | 281 | 527 | ||||||
Provision for bad debts | (162) | 1,263 | ||||||
Provision for sales returns | — | 87 | ||||||
Inventory write-offs and disposals | (117) | — | ||||||
Amortization of discount on lines of credit | 126 | 123 | ||||||
Amortization of debt issuance costs | 290 | 240 | ||||||
Patent litigation mark-to-market | 190 | — | ||||||
Change in fair value of warrants | — | (5,850) | ||||||
Issuance of restricted shares | 164 | — | ||||||
Issuance costs for common stock warrants | — | 1,640 | ||||||
Stock-based compensation | 1,488 | 2,367 | ||||||
Gain on debt forgiveness | (3,014) | — | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (417) | 4,017 | ||||||
Inventory | (2,788) | (1,597) | ||||||
Prepaid expenses and other current assets | 235 | 430 | ||||||
Accounts payable and accrued liabilities | 705 | (3,445) | ||||||
Deferred revenue | 292 | (562) | ||||||
Net cash and cash equivalents used in operating activities | (13,606) | (11,447) | ||||||
Cash Flows from Investing Activities: | ||||||||
Purchases of property, plant, and equipment | (396) | (78) | ||||||
Net cash and cash equivalents used in investing activities | (396) | (78) | ||||||
Cash Flows from Financing Activities: | ||||||||
Proceeds from the sale of common stock | 13,291 | 6,912 | ||||||
Proceeds from the sale of common stock warrants | — | 15,300 | ||||||
Proceeds from the issuance of Series F Convertible Preferred Stock | — | 2,700 | ||||||
Payments of equity offering costs | (6) | (1,281) | ||||||
Payment of July 2020 Warrant issuance costs | — | (1,640) | ||||||
Borrowings on other long-term loans | — | 3,140 | ||||||
Principal payment on loan | — | (700) | ||||||
Borrowings on credit facility | — | 3,000 | ||||||
Repayment of credit facility | — | (3,000) | ||||||
Proceeds from the exercise of common stock warrants | 16,560 | 46 | ||||||
Payment of debt issuance costs | (25) | (75) | ||||||
Proceeds from exercise of stock options | 66 | — | ||||||
Net cash and cash equivalents provided by financing activities | 29,886 | 24,402 | ||||||
Effect of exchange rate changes | (171) | 181 | ||||||
Increase in cash, cash equivalents and restricted cash | 15,713 | 13,058 | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 17,876 | 6,101 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 33,589 | $ | 19,159 | ||||
Supplemental cash flow disclosure: | ||||||||
Cash paid for interest | $ | 1,328 | $ | 1,438 | ||||
Cash received for interest | $ | 44 | $ | — | ||||
Cash paid for income taxes | $ | 154 | $ | 21 | ||||
Cash paid for operating leases | $ | 185 | $ | 417 | ||||
Non-cash settlement of liability | $ | 510 | $ | 151 | ||||
Non-cash right-of-use assets obtained in exchange for lease obligation | $ | 48 | $ | 2,037 | ||||
Deemed dividend on preferred stock | $ | 546 | $ | 17,378 | ||||
Warrants issued in connection with debt instruments | $ | — | $ | 67 | ||||
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, loss on patent litigation settlement, stock-based and other non-cash compensation, debt forgiveness, other net income, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC. Reconciliation of GAAP Net Loss to Adjusted EBITDA and GAAP Net Loss Per Share to Adjusted EBITDA Per Share (Unaudited, in thousands, except per share data)
| ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
GAAP net loss attributable to common stockholders | $ | (3,285) | $ | (17,366) | $ | (11,425) | $ | (28,065) | ||||||||
Deemed dividend on convertible preferred stock | 9 | 17,378 | 546 | 17,378 | ||||||||||||
GAAP net income (loss) | $ | (3,276) | $ | 12 | $ | (10,879) | $ | (10,687) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 569 | 568 | 1,727 | 1,782 | ||||||||||||
Income tax provision (benefit) | 14 | 15 | (7) | 49 | ||||||||||||
Depreciation and amortization | 101 | 46 | 281 | 527 | ||||||||||||
Change in allowance for doubtful accounts | (83) | 256 | (162) | 1,263 | ||||||||||||
Loss on patent litigation settlement | 29 | — | 190 | — | ||||||||||||
Stock-based and other non-cash compensation | 192 | 847 | 1,488 | 2,367 | ||||||||||||
Gain on debt forgiveness | — | — | (3,014) | — | ||||||||||||
Other (income) expense, net | — | (4,209) | — | (4,209) | ||||||||||||
Adjusted EBITDA | $ | (2,454) | $ | (2,465) | $ | (10,376) | $ | (8,908) | ||||||||
GAAP net loss attributable to common stockholders per share, basic and diluted | $ | (0.02) | $ | (0.21) | $ | (0.08) | $ | (0.56) | ||||||||
Deemed dividend on convertible preferred stock | — | 0.21 | — | 0.35 | ||||||||||||
GAAP net loss per share, basic and diluted | $ | (0.02) | $ | — | $ | (0.08) | $ | (0.21) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | — | 0.01 | 0.01 | 0.04 | ||||||||||||
Income tax provision (benefit) | — | — | — | — | ||||||||||||
Depreciation and amortization | — | — | — | 0.01 | ||||||||||||
Change in allowance for doubtful accounts | — | — | — | 0.03 | ||||||||||||
Loss on patent litigation settlement | — | — | — | — | ||||||||||||
Stock-based and other non-cash compensation | — | 0.01 | 0.01 | 0.05 | ||||||||||||
Gain on debt forgiveness | — | — | (0.02) | — | ||||||||||||
Other (income) expense, net | — | (0.05) | — | (0.10) | ||||||||||||
Adjusted EBITDA per share, basic and diluted | $ | (0.02) | $ | (0.03) | $ | (0.08) | $ | (0.18) | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-46-revenue-growth-in-2021-third-quarter-demand-for-dental-lasers-from-new-customers-remains-high-and-continues-to-fuel-growth-301421567.html
SOURCE BIOLASE, Inc.
FAQ
What were BIOL's Q3 2021 financial results?
What is BIOL's revenue guidance for Q4 2021?
How did BIOL's international revenue perform in Q3 2021?
What was BIOL's net loss for Q3 2021?
What impact did COVID-19 have on BIOL's revenue?
